Palonosetron Kalceks

Palonosetron, the active ingredient in Palonosetron Kalceks, is a 5-HT3 receptor antagonist presented as a 0.075 mg/2 ml solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative recovery in adult patients.

GNH USA supplies Palonosetron Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Kalceks is a selective 5‑HT3 receptor antagonist indicated for several nausea‑vomiting pathways. - Chemotherapy‑induced nausea and vomiting (CINV): provides effective prophylaxis in patients receiving highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting after surgery. - Radiotherapy‑induced nausea and vomiting (RINV): helps control nausea associated with radiation treatment. - Anticipatory nausea and vomiting: lessens nausea that occurs before chemotherapy in patients with a history of CINV.

Palonosetron may cause adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Fatigue: general tiredness without specific cause. - Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects: - QT interval prolongation: may affect cardiac rhythm. - Severe hypersensitivity: including rash, pruritus, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Persistent arrhythmia: uncommon cardiac rhythm disturbances.

When prescribing Palonosetron Kalceks, clinicians should consider several safety aspects. - Cardiac monitoring: assess baseline ECG in patients with known QT prolongation risk. - Concomitant serotonergic drugs: evaluate for additive serotonin effects. - Renal impairment: adjust clinical judgment in severe kidney dysfunction. - Hepatic impairment: use caution in patients with significant liver disease. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Palonosetron may interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Class I anti‑arrhythmic drugs (e.g., quinidine) that prolong QT interval. - Other potent 5‑HT3 antagonists used concurrently.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs, tramadol) – monitor for serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole) – may increase palonosetron plasma levels. - CYP3A4 inducers (e.g., rifampicin) – may reduce palonosetron exposure.